Search - tctmd.com

Displaying 1 - 20 of 279

Sort: Relevancy | Date

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

L.A. McKeown

February 04, 2026

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

Heart Disease Remains Number One Killer of Americans

L.A. McKeown

January 22, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

JACC Debuts Data Digest on CV Health in the United States

Caitlin E. Cox

January 12, 2026

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Todd Neale

January 05, 2026

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Caitlin E. Cox

July 21, 2025

News Conference News HRS 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Todd Neale

April 28, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Advertisement

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Heart Disease Remains Number One Killer of Americans

January 2026 Dispatch for the CV Team

JACC Debuts Data Digest on CV Health in the United States

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

December 2025 Dispatch for the CV Team

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

April 2025 Dispatch for the CV Team

Weekend Warriors Also See Mortality Benefits With Exercise

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content